Showing results (111-120 of 122) with videos related to
Sort By:
Pageof 13
Access Microbiology|October 2, 2020
First hybrid complete genome of <i>Aeromonas veronii</i> reveals chromosome-mediated novel structural variant <i>mcr-3.30</i> from a human clinical sampleNaveen Kumar Devanga Ragupathi, Dhiviya Prabaa Muthuirulandi Sethuvel, Shalini Anandan, et al.Archives of Pharmacal Research|October 15, 2014
Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activationNagaraj M Kulkarni, Milind M Muley, Mallikarjun S Jaji, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 19, 2026
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort StudySelwyn Selva Kumar D, Nishi Somarkutty, Jayavelu Hariram Prasad D, et al.Bioorganic & Medicinal Chemistry Letters|August 29, 2006
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3Jack J Chen, Kumar D Thakur, Michael P Clark, et al.Nature Communications|November 10, 2022
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutationsIris K van Alderwerelt van Rosenburgh, David M Lu, Michael J Grant, et al.Human Molecular Genetics|May 24, 2017
Genotype-phenotype correlation in patients with isovaleric acidaemia: comparative structural modelling and computational analysis of novel variantsOsama K Zaki, George Priya Doss C, Salsabil A Ali, et al.Cell Reports|December 20, 2023
Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranesKrishna C Mudumbi, Eric A Burns, David J Schodt, et al.Biorxiv : the Preprint Server for Biology|April 24, 2023
Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranesKrishna C Mudumbi, Eric A Burns, David J Schodt, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2023
Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort StudyAbi Manesh, Priyanka Gautam, Selwyn Selva Kumar D, et al.Bioorganic & Medicinal Chemistry Letters|December 27, 2006
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)Michael P Clark, Kelly M George, Roger G Bookland, et al.Pageof 13